Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
Treatment with interferon beta-1a plus the antiviral remdesivir was not superior to remdesivir alone.
The anti-inflammatory and antiviral drug combination reduced time to recovery for people hospitalized with COVID-19.
Arthritis drug Olumiant (baricitinib) can be used in combination with remdesivir.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The prevalence of abnormal liver tests in people hospitalized with COVID-19 is higher than previously found.
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.
HIV-positive people appear no more likely to contract the new coronavirus or to become seriously ill.
Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.